Cargando…
Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
Introduction: Development of Poly (ADP-ribose) polymerase (PARP) inhibitors has been extensively studied in cancer treatment. Olaparib, the first approved PARP inhibitor, showed potency in the inhibition of both BRCA (breast cancer associated)-mutated and BRCA-unmutated cancers. Methods: Aiming to t...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868654/ https://www.ncbi.nlm.nih.gov/pubmed/36699082 http://dx.doi.org/10.3389/fphar.2022.1054616 |